← Scroll for more →
Prokidney Corp. (PROK)
Biological Products, (No Diagnostic Substances)
Latest Price
$1.11
Market Cap
$68.31M
TTM P/E
--
Earnings Yield
--
TTM Div Yield
--
P/B Ratio
--
Price at the 2026-11-06 close. Earnings yield is trailing 12-month earnings divided by price.
Price
full chart →- 1-Year Change
- -59.43%
- 52-Week High
- $2.95
- 52-Week Low
- $0.87
Daily close, 2025-11-06 to 2026-11-06
Financials
financial statements →| Quarter ending | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Last 4 quarters |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $76,000 | $230,000 | $221,000 | $217,000 | $225,000 | $226,000 | $150,000 | $818,000 |
| Operating margin | -- | -- | -- | -67856.6% | -17994.8% | -17967.9% | -17759.9% | -20164.9% | -19881.9% | -32248.7% | -21664.5% |
| Net income | -$9.49M | -$12.51M | -$17.91M | -$21.28M | -$16.73M | -$16.55M | -$16.47M | -$19.23M | -$20.04M | -$28.42M | -$84.16M |
| Net margin | -- | -- | -- | -27997.4% | -7275.6% | -7489.6% | -7589.4% | -8547.1% | -8865.9% | -18948.0% | -10288.4% |
| Operating cash flow | -$34.65M | -$38.29M | -$29.24M | -$24.17M | -$29.59M | -$31.42M | -$26.60M | -$32.51M | -$41.68M | -$40.37M | -$141.17M |
| Free cash flow | -$35.61M | -$38.93M | -$31.64M | -$49.68M | -$30.73M | -$34.53M | -$31.79M | -$38.27M | -$45.47M | -$44.21M | -$159.73M |
Chart: revenue per quarter, Mar 2024 to Jun 2026. Hover over or tap a row to chart it.
Quarters ending Sep 2024 to Jun 2026, oldest first.
Revenue ($K)
Last 4 quarters $818,000
$250K$0
076230221217225226150
Operating margin (%)
Last 4 quarters -21664.5%
0%-80000%
---68K-18K-18K-18K-20K-20K-32K
Net income ($M)
Last 4 quarters -$84.16M
$0-$30M
-18-21-17-17-16-19-20-28
Net margin (%)
Last 4 quarters -10288.4%
0%-30000%
---28K-7K-7K-8K-9K-9K-19K
Operating cash flow ($M)
Last 4 quarters -$141.17M
$0-$50M
-29-24-30-31-27-33-42-40
Free cash flow ($M)
Last 4 quarters -$159.73M
$0-$50M
-32-50-31-35-32-38-45-44
Capital Structure
balance sheet →- Shares Outstanding
- 61.54M
- Total Debt
- --
- Long-term Debt
- --
- Long-term Debt / Capital
- --
- Cash
- $74.87M
- Current Assets
- $189.77M
- Current Liabilities
- $22.71M
Current position as of 2026-06-30.
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Montanova Capital, LLC | 12.34M | $25.0M | 20.05% | -- | 2026-06-30 |
| Morgan Stanley | 9.85M | $20.0M | 16.01% | +898.2K | 2026-06-30 |
| BlackRock, Inc. | 5.20M | $10.0M | 8.45% | +3.81M | 2026-06-30 |
| Geode Capital Management, LLC | 2.39M | $4.0M | 3.88% | +1.16M | 2026-06-30 |
| Bleichroeder LP | 2.00M | $4.0M | 3.25% | -- | 2026-06-30 |
| Hennion & Walsh Asset Management, Inc. | 1.85M | $3.0M | 3.00% | +236.1K | 2026-06-30 |
| Artia Global Partners LP | 1.81M | $3.0M | 2.94% | -- | 2026-06-30 |
| Vanguard Capital Management LLC | 1.18M | $2.0M | 1.91% | +28.3K | 2026-06-30 |
| Renaissance Technologies LLC | 1.10M | $2.0M | 1.79% | -151.4K | 2026-06-30 |
| Millennium Management LLC | 1.05M | $2.0M | 1.71% | -1.22M | 2026-06-30 |
Recent Material Events
all events →- ProKidney Corp. disclosed that its cash, cash equivalents, and marketable securities totaled $141.9 million as of September 30, 2026. The company also furnished an updated investor presentation detailing the ongoing Phase 3 PROACT 1 trial for rilparencel, a potential first-in-class autologous cell therapy for advanced chronic kidney disease. Topline data for the trial's surrogate endpoint is expected in Q2 2027, with current cash reserves projected to fund operations into mid-2027. ProKidney Corp. operates as a biotechnology company developing regenerative medicine therapies.
- ProKidney Corp. entered into an Open Market Sale Agreement with Jefferies LLC to sell up to $200 million of its Class A common stock in at-the-market offerings. The company has no obligation to sell any shares and may suspend the offering at any time. Jefferies will receive compensation of up to 3.0% of gross proceeds plus specified expenses. This offering is subject to the effectiveness of a shelf registration statement on Form S-3 filed concurrently with this report. ProKidney Corp. operates in the biotechnology industry, focusing on developing therapies for kidney disease.
Insider Transactions
all insider transactions →| Name | Title | Transaction | Shares | Price | Date |
|---|---|---|---|---|---|
| Weber Darin J. | Chief Regulatory Officer | Conversion | 200.0K | -- | 2026-10-28 |
| Pereira Brian JG | -- | Conversion | 675.2K | -- | 2026-08-04 |
| Pereira Brian JG | -- | Conversion | 81.9K | -- | 2026-08-04 |
| Girolamo Todd C | Chief Legal Officer | Conversion | 163.9K | -- | 2026-06-12 |
| Control Empresarial de Capitales S.A. de C.V. | -- | Conversion | 63.12M | -- | 2026-04-28 |